Hansa Biopharma AB (publ) (STO:HNSA)
45.14
-2.18 (-4.61%)
Nov 20, 2026, 5:29 PM CET
Hansa Biopharma AB Market Cap
Hansa Biopharma AB has a market cap or net worth of 4.59 billion as of November 20, 2026. It is the 14,435th most valuable company in the world and the 189th biggest in Sweden. Its market cap has increased by 66.20% in one year.
Market Cap
4.59B
Enterprise Value
4.20B
Revenue
301.64M
Global Rank
Country Rank
#189 Sweden
PE Ratio
n/a
ChartMarket Cap Chart
Since April 24, 2008, Hansa Biopharma AB's market cap has increased from 30.71M to 4.59B, an increase of 14,856.84%. That is a compound annual growth rate of 30.92%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 4.59B | 31.37% |
| Dec 30, 2025 | 3.50B | 31.53% |
| Dec 30, 2024 | 2.66B | 93.47% |
| Dec 29, 2023 | 1.37B | -46.77% |
| Dec 30, 2022 | 2.58B | -34.64% |
| Dec 30, 2021 | 3.95B | -63.06% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| BioArctic AB | 26.67B |
| Egetis Therapeutics AB | 5.17B |
| Vicore Pharma Holding AB | 2.77B |
| Saniona AB | 1.55B |
| Genovis AB (publ.) | 1.53B |
| Flerie AB | 1.08B |
| Infant Bacterial Therapeutics AB | 934.92M |
| AlzeCure Pharma AB | 783.26M |